TreeFrog Therapeutics Collaborates with University of Pittsburgh
TreeFrog Therapeutics has announced an exciting research collaboration with the University of Pittsburgh, focused on advancing the potential of tertiary lymphoid structures (TLS) in the rapidly evolving field of immuno-oncology. This innovative partnership aims to explore the intersection of biotechnology and cancer treatment.
Unleashing the Power of Tertiary Lymphoid Structures
This collaboration is powered by the groundbreaking research led by Dr. Tullia Bruno, an Assistant Professor in the Department of Immunology at the University of Pittsburgh, alongside her dedicated team at UPMC Hillman Cancer Center. By combining their insights with TreeFrog Therapeutics' proprietary C-Stem™ 3D cell encapsulation technology, the collaboration seeks to push the boundaries of 3D immunology.
Understanding TLS Functionality
Tertiary lymphoid structures (TLS) are ectopic lymphoid formations that typically arise in response to chronic infections, autoimmune conditions, and inflammatory responses, notably in solid tumors. These structures play an essential role in modulating the immune response against cancer by creating localized immune activation. The team’s objective is to shed light on the complex mechanisms that dictate TLS behavior and explore novel therapeutic strategies.
Benefits of the Collaboration
“We're thrilled to embark on this journey with Professor Bruno to leverage our encapsulation technology to understand and manipulate TLS. Our research indicates that TLS presence can enhance anti-tumor immunity and lead to better patient outcomes,” expressed Maxime Feyeux, Chief Scientific Officer at TreeFrog Therapeutics.
Exploring New Frontiers in Cancer Treatment
Professor Bruno also shared her enthusiasm regarding the collaboration: “If we can recreate TLS using our 3D technologies, we could answer numerous questions about their formation and regulation. This approach could significantly enhance our understanding of TLS biology, especially in conjunction with patient samples and relevant animal models.”
About TreeFrog Therapeutics
TreeFrog Therapeutics, a French regenerative medicine biotech company, is on a mission to facilitate access to cell therapies for millions of patients worldwide. Their unique methodology in cell therapy development integrates expertise from biophysicists, cell biologists, and production engineers, addressing pivotal challenges in the field by producing high-quality, scalable cell therapies effectively and affordably.
The organization's commitment to making cell therapies accessible is encapsulated in their motto: Cell Therapy for all. To achieve this goal, TreeFrog not only pursues its proprietary therapies but also forges partnerships with prominent biotech firms and industry stakeholders. Over the last three years, the company has successfully raised $82 million, propelling the advancement of their stem cell-based therapeutic pipeline in regenerative medicine.
In 2022, TreeFrog Therapeutics expanded its global footprint by establishing technological hubs in Boston, USA, and Kobe, Japan, fostering the expansion and integration of their innovative C-Stem™ platform while planting seeds for strategic alliances in the biotech landscape.
Frequently Asked Questions
What is the focus of the collaboration between TreeFrog Therapeutics and the University of Pittsburgh?
The collaboration aims to explore the role of tertiary lymphoid structures in immuno-oncology, leveraging advanced 3D cell encapsulation technology.
Who is leading the research on tertiary lymphoid structures?
Dr. Tullia Bruno, an Assistant Professor in the Department of Immunology at the University of Pittsburgh, is leading the research.
How does TreeFrog Therapeutics' technology work?
TreeFrog employs proprietary C-Stem™ technology for 3D cell encapsulation, enhancing the ability to produce and manipulate cell therapies.
What are tertiary lymphoid structures?
Tertiary lymphoid structures are abnormal lymphoid formations that arise in response to chronic conditions and play a significant role in the immune response against tumors.
What is TreeFrog's mission regarding cell therapies?
TreeFrog's mission is to make cell therapies accessible to millions, operating under the tagline Cell Therapy for all.
